Delving into the Latest Updates on GSK-3536820A with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries.
The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine aged for different lengths of time by storage at 2-8ºC.

Start Date30 Aug 2018

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with GSK-3536820A

Login to view more data

100 Translational Medicine associated with GSK-3536820A

Login to view more data

100 Patents (Medical) associated with GSK-3536820A

Login to view more data

100 Deals associated with GSK-3536820A

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03433482 (CTgov)	Phase 2	Meningitis, Meningococcal	1,707	MenACWY liquid (GSK3536820A ACWY_Liq24 Group)	bwealkijgs(ihmugmwzni) = yeksbaqgyn ygruxxxjpi (uuxvspcgco, tmqjjfopbj - dykslbaalm) View more	-	17 Feb 2021
				MenACWY (ACWY_1 Group)	bwealkijgs(ihmugmwzni) = cwgevqmjra ygruxxxjpi (uuxvspcgco, ibxzmmztcm - rnncwkomjm) View more